Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
KLF1 encodes KLF transcription factor 1 (362 aa). Transcription regulator of erythrocyte development that probably serves as a general switch factor during erythropoiesis. Is a dual regulator of fetal-to-adult globin switching. Highest expression in Whole Blood (21.6 TPM) and Spleen (1.4 TPM).
Anemia, congenital dyserythropoietic, type IVb is associated with mutations in the KLF1 gene on chromosome 19.
The KLF1 protein participates in Expression of KLF15, GATA3, CHD4, EP300, NFATC2 (NFAT1), FOS:JUN (AP-1), KLF13, and MAF bind the IL4 gene, and GATA3, CHD4, EP300, NFATC2 (NFAT1), FOS:JUN (AP-1), KLF13, MAF, YY1, ETS1, POU2F1 (OCT1), POU2F2 (OCT2), BATF, SATB1, IRF4, SMARCA4, and STAT6 positively regulate expression of IL4 pathways.
KLF1 is classified as a druggable target (Transcription Factor category) with score 0.0.
Genetic testing for KLF1 is available. Testing is considered confirmatory for diagnosis.
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 11:35 AM UTC
Online Mendelian Inheritance in Man